Core Viewpoint - Spero Therapeutics has appointed Esther Rajavelu as President and CEO, effective May 2, 2025, following her role as Interim President since January 2025, and she will also be nominated for the Board of Directors [1][2][3] Leadership Transition - Esther Rajavelu has been recognized for her leadership and focus on advancing Spero's programs and partnerships, particularly with GSK [2] - Rajavelu will continue her roles as Chief Financial Officer and Treasurer while succeeding Sath Shukla, who will step down from both his CEO position and the Board of Directors [3] Clinical Development Focus - The company is prioritizing the PIVOT-PO Phase 3 trial for tebipenem HBr, with an update expected this quarter [3] - The clinical program for tebipenem HBr is highlighted as the highest priority for Spero, indicating a strong commitment to advancing this treatment [3] Company Overview - Spero Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focusing on novel treatments for rare diseases and multi-drug resistant bacterial infections [4]

Financial Data and Key Metrics Changes - As of December 31, 2024, Spero had cash and cash equivalents of $52.9 million [22] - Total revenue for Q4 2024 was $15 million, down from $73.5 million in Q4 2023 [23] - Total revenue for the year ended December 31, 2024, was $48 million compared to $103.8 million for the year ended December 31, 2023 [23] - R&D expenses for Q4 2024 were $28.8 million, up from $16.6 million in Q4 2023 [24] - The company reported a net loss of $20.7 million for Q4 2024 and a net loss of $68.4 million for the year ended December 31, 2024 [25][26] Business Line Data and Key Metrics Changes - The tebipenem HBr program is in a Phase 3 trial, with an interim analysis expected in Q2 2025 [8][12] - SPR720, a novel gyrase B inhibitor, did not meet its primary endpoint in a Phase IIa study [10][11] - Development of SPR206 has been discontinued following a thorough review [12] Market Data and Key Metrics Changes - There are an estimated 3.4 million episodes of complicated UTIs reported annually in the U.S., which are a leading cause of hospitalizations [14] - Complicated UTIs are often caused by multidrug-resistant pathogens, highlighting the need for effective treatments [15][16] Company Strategy and Development Direction - The primary focus for 2025 is the advancement of the tebipenem program, which could change the treatment paradigm for complicated UTIs [8][12] - Following the completion of the tebipenem HBr Phase 3 trial, GSK is expected to take over regulatory and commercialization efforts [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about completing the interim analysis and providing updates in Q2 2025 [45] - The company is assessing the full data set from the SPR720 trial to determine next steps, including potential reformulation strategies [41] Other Important Information - The company has approximately $47.5 million in earned and noncontingent development milestones from GSK, which will fund operations into Q2 2026 [22] Q&A Session Summary Question: Does the trial get unblinded if the interim is successful? - Yes, if the interim is successful, the independent data monitoring committee will manage the unblinding process [29] Question: Is there any reason to keep running the trial longer even if the trial is positive early on? - Management cannot speculate on that until the interim analysis is completed [32] Question: What are the potential paths forward for SPR720? - The first step is to complete the data analysis of the full 25 patients dosed in the trial to determine the best path forward [40]

Financial Data and Key Metrics Changes - As of December 31, 2024, Spero had cash and cash equivalents of $52.9 million [22] - Total revenue for Q4 2024 was $15 million, down from $73.5 million in Q4 2023; total revenue for the year ended December 31, 2024, was $48 million compared to $103.8 million in 2023 [23] - R&D expenses for Q4 2024 were $28.8 million, up from $16.6 million in Q4 2023; for the year, R&D expenses were $97 million compared to $51.4 million in 2023 [24] - The company reported a net loss of $20.7 million for Q4 2024 and a net loss of $68.4 million for the year [25] Business Line Data and Key Metrics Changes - The tebipenem HBr program is the most advanced, currently in a Phase 3 trial aimed at treating complicated urinary tract infections [7] - SPR720, a novel gyrase B inhibitor, did not meet its primary endpoint in a Phase IIa proof-of-concept study [10][11] - Development of SPR206 has been discontinued following a thorough review and reprioritization [12] Market Data and Key Metrics Changes - There are an estimated 3.4 million episodes of complicated UTIs reported annually in the U.S., which are a leading cause of hospitalizations [14] - Complicated UTIs are often caused by multidrug-resistant pathogens, highlighting the need for effective treatments [15] Company Strategy and Development Direction - The primary focus for 2025 is the advancement of the tebipenem program, which could change the treatment paradigm for complicated UTIs by providing an oral option [8] - Following the completion of the tebipenem HBr Phase 3 trial, GSK is expected to take over regulatory and commercialization responsibilities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about completing the interim analysis for the tebipenem trial in Q2 2025 and the potential for significant milestones from GSK [13][45] - The company is assessing the full data set from the SPR720 trial to determine next steps, indicating a cautious but proactive approach to its pipeline [41] Other Important Information - The company has approximately $47.5 million in earned and noncontingent development milestones from GSK, which will support operations into Q2 2026 [22] Q&A Session Summary Question: Does the trial get unblinded if the interim is successful? - Yes, if the interim is successful, the independent data monitoring committee will manage the unblinding process [29] Question: Is there any reason to keep running the trial longer even if the trial is positive early on? - Management cannot speculate on that until the interim analysis is completed [32] Question: What are the potential paths forward for SPR720? - The first step is to complete the data analysis of the full 25 patients dosed in the trial, which will inform the next steps [40]

Company Performance - Spero Therapeutics reported a quarterly loss of $0.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and a significant decline from earnings of $0.96 per share a year ago, indicating an earnings surprise of -8.57% [1] - The company posted revenues of $15.04 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 21.32%, but this represents a decline from year-ago revenues of $73.52 million [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Spero Therapeutics shares have declined approximately 13.6% since the beginning of the year, contrasting with the S&P 500's decline of -2.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.33 on $11 million in revenues, and for the current fiscal year, it is -$0.79 on $60 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Development and Clinical Trials - The company suspended development of the SPR720 oral program due to an interim analysis indicating it did not meet its primary endpoint, highlighting potential safety issues [231]. - The focus has shifted to advancing the tebipenem HBr program, which is now substantially dependent on collaboration with GSK [232]. - The company has no products approved for sale and has invested significantly in the tebipenem HBr program for treating cUTI [233]. - The FDA approval timeline for tebipenem HBr remains uncertain, which could impact its commercialization prospects [233]. - Clinical trials are subject to risks of failure, including inability to demonstrate efficacy or compliance with regulatory requirements [235]. - Delays in patient enrollment for clinical trials could significantly increase development costs and hinder the approval process [245]. - The company must submit a diversity action plan for Phase 3 clinical trials, which may affect planning and timing [246]. - Preliminary data from clinical studies may change as more data becomes available, potentially impacting the development path [248]. - The company has discontinued development of SPR206 as part of its strategic re-prioritization [231]. - Serious adverse events or undesirable side effects could delay or prevent regulatory approval, limit commercial potential, or result in significant negative consequences post-approval [251]. - The company may need to abandon or limit the development of product candidates if unexpected adverse events occur during clinical trials [252]. - The company has substantial ongoing and planned clinical trials, but the success of these trials is uncertain and may not yield viable product candidates [279]. - The company plans to prioritize advancing Phase 3 clinical trial activities for tebipenem HBr and completing analysis of data from 25 treated patients in the Phase 2a trial of SPR720 [300]. - The company has received fast track designation for tebipenem HBr and SPR720, but this does not guarantee faster approval or marketing authorization [392]. - The lengthy and unpredictable regulatory approval process could significantly harm the company's business and financial condition if product candidates do not receive approval [390]. - The company must demonstrate the safety and efficacy of its product candidates to regulatory agencies, and failure to do so could prevent commercialization [387]. Financial Performance and Funding - The company has not generated any revenue from product sales and has incurred losses since its inception in 2013, with a net loss of $68.6 million for the year ended December 31, 2024 [299]. - The company is focusing on the development and commercialization of therapeutics to treat drug-resistant bacterial infections, particularly through its product candidate tebipenem HBr [278]. - The company has a history of losses and expects to incur substantial future losses, raising concerns about its ability to continue as a going concern [298]. - The company is anticipating needing substantial additional funding to support ongoing and planned clinical trials and product development [305]. - The company filed a new universal shelf registration statement to raise up to $300 million, which includes $75 million of common stock available for issuance [309]. - The company's public float was approximately $45.1 million as of March 21, 2025, limiting its ability to raise capital under the "baby shelf rules" until it exceeds $75 million [310]. - The company may need to relinquish rights to technologies or product candidates if it raises additional funds through collaborations or licensing arrangements [312]. - The company expects to incur significant expenses and operating losses as it advances product candidates through clinical development and marketing approval [301]. - Coverage and reimbursement availability from government health programs and third-party payors are critical for the commercial success of outpatient products [274]. Regulatory and Compliance Risks - The company faces significant variability in safety and efficacy results across clinical trials, which may impact the ability to obtain marketing approval for product candidates [249]. - The company faces significant risks related to compliance with healthcare laws and regulations, which could lead to criminal sanctions, civil penalties, and diminished profits [408]. - The company anticipates substantial costs to ensure compliance with healthcare regulations, with potential penalties for non-compliance including exclusion from government-funded healthcare programs [409]. - The company must comply with numerous laws and regulations related to government contracts, which can complicate business operations and increase costs [356]. - The company is subject to numerous environmental, health, and safety laws, which could result in significant compliance costs and potential liabilities [283]. - The company faces risks related to product liability claims, which could divert resources and limit commercialization efforts [281]. - The company must comply with evolving data protection laws, which could increase compliance costs and expose it to regulatory risks [291]. - The company is obligated to meet specific diligence requirements and milestone payments under licensing agreements, such as up to $1.0 million for regulatory milestones [344]. Market and Competitive Landscape - Market acceptance of approved product candidates is uncertain, and failure to achieve sufficient acceptance could adversely affect revenue generation [255]. - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may hinder its ability to compete effectively [266]. - Pricing regulations and reimbursement policies in various countries could negatively affect the commercial launch and revenue potential of approved products [270]. - The potential for bacterial resistance to product candidates could affect their revenue potential if approved [276]. - The company relies on third parties for clinical trials and manufacturing, which limits control and increases risks related to compliance and performance [328][333]. - Supply chain disruptions have increased costs of raw materials and shipping, potentially impacting the company's ability to produce and deliver products [336]. - The company does not have long-term agreements with third-party manufacturers, which poses risks of delays in production if any manufacturer becomes unavailable [334]. Intellectual Property and Legal Risks - The patent position is uncertain, and changes in patent laws may affect the scope and enforceability of the company's patent rights [363]. - The company faces risks related to the potential invalidation or narrowing of patent claims, which could limit the ability to protect technology and products [370]. - The company may face expensive and time-consuming lawsuits to protect its intellectual property, which could adversely affect its competitive position and financial condition [371]. - The company’s commercial success depends on its ability to develop and market product candidates without infringing on third-party intellectual property rights [374]. - The biotechnology and pharmaceutical industries are prone to substantial intellectual property litigation, which could limit the company's ability to commercialize its product candidates [375]. - If the company is found to infringe on third-party intellectual property rights, it may be forced to cease development or obtain licenses that may not be available on commercially reasonable terms [376]. - The company relies on trade secrets and non-disclosure agreements to protect its proprietary information, but breaches could harm its competitive position [379]. Operational Challenges - The company implemented a restructuring plan on October 29, 2024, reducing its workforce by approximately 39% [428]. - The company relies heavily on key executives and personnel, with high turnover rates posing a risk to its business strategy [427]. - The company faces challenges in attracting and retaining qualified personnel due to intense competition within the pharmaceutical and biotechnology sectors [429]. - Disruptions caused by the COVID-19 pandemic have led to postponed inspections, which may affect the FDA's ability to process regulatory submissions [423]. - The political process affecting government funding for the FDA and SEC is fluid and unpredictable, which may impact the company's operations [421]. - The company is uncertain about the impact of potential future government shutdowns on its access to public markets and necessary capital [423]. Collaboration and Partnerships - Any termination of the GSK License Agreement could materially adversely affect the company's business and prospects [232]. - Collaboration agreements may not result in efficient development or commercialization of product candidates, especially if collaborators undergo business combinations [322]. - The company faces significant competition in establishing collaborations for product candidates, which may lead to risks such as collaborators not performing their obligations as expected [321]. - Recent business combinations among large pharmaceutical companies have reduced the number of potential collaborators, impacting future collaboration opportunities [324]. - Failure to establish timely agreements with suitable collaborators may result in curtailed development programs or increased expenditures for the company [325]. - The company is responsible for the execution and costs of the follow-up Phase 3 clinical trial of tebipenem HBr, while GSK handles further development and commercialization outside the U.S. [346].

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprior ...

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to d ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in B ...

Core Insights - Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections [1][3] - Esther Rajavelu, the Interim President and CEO of Spero, will present at the TD Cowen 45 Annual Health Care Conference in Boston from March 3 to 5, 2025 [1][2] Company Overview - Spero Therapeutics is headquartered in Cambridge, Massachusetts, and is engaged in identifying and developing novel treatments for rare diseases and MDR bacterial infections [3] - The company provides an opportunity for one-on-one meetings during the conference, indicating a proactive approach to investor relations [1][2] Event Details - The company presentation is scheduled for March 5, 2025, at 3:10 PM ET [2] - A webcast of the presentation will be available on Spero Therapeutics' website, with a replay accessible after the event [2]

Core Viewpoint - Spero Therapeutics, Inc. (SPRO) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Spero Therapeutics indicate an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - The upgrade of Spero Therapeutics to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for Spero Therapeutics - For the fiscal year ending December 2024, Spero Therapeutics is expected to earn -$1.20 per share, reflecting a year-over-year change of -379.1% [8]. - Over the past three months, the Zacks Consensus Estimate for Spero Therapeutics has increased by 48.5%, indicating positive sentiment among analysts [8].